

Sheinberg, Samuel I.

From: HSRHelp
Sent: Friday, May 19, 2023 10:17 AM
To: Berg, Karen E.; Musick, Vesselina; Siffer, Kristin; Sheinberg, Samuel.; Six, Anne; Whitehead, Nora; Fetterman, Michelle
Subject: FW: Informal Interpretation Request re: exclusive pharma license

From: Walsh, Kathryn E. <kwalsh@ftc.gov>
Sent: Friday, May 19, 2023 10:17:15 AM (UTC-05:00) Eastern Time (US & Canada)
To: [REDACTED]
Cc: HSRHelp <HSRHelp@ftc.gov>
Subject: FW: Informal Interpretation Request re: exclusive pharma license

We disagree. Your filing will cover whatever exclusive licenses will become effective during the year after filing. Any licenses that become effective after that are potentially reportable. ¹

From:
Sent: Thursday, May 18, 2023 12:36:32 PM (UTC-05:00) Eastern Time (US & Canada)
To: HSRHelp <HSRHelp@ftc.gov>
Cc:
Subject: Informal Interpretation Request re: exclusive pharma license

Agreement. In the event a License
Comp
milestones, and the License Agre
Product(s).

Please do not hesitate to let us know if you require further facts to aid you.
Sincerely,

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]